D. Ross Camidge
University of Colorado, Denver, CO, USAAuthored Items
Andrea Ardizzoni, Anna F. Farago, Akin Atmaca, Emiliano Calvo, Fiona Taylor, Bryan Bennett, Giovanni Selvaggi, Anne Pieters, John R. Penrod, Yong Yuan, D. Ross Camidge
November 2018 Vol 9, NO 11
CheckMate 032 (NCT01928394) is an open-label, phase 1/2 trial evaluating the efficacy and safety of nivolumab monotherapy and nivolumab plus ipilimumab in patients with advanced or metastatic solid tumors. In this study, nivolumab alone or in combination with ipilimumab showed durable responses, encouraging survival, and manageable safety in patients with small cell lung cancer (SCLC) that progressed after ≥1 previous platinum-containing regimens.
Last modified: November 15, 2018